Overview

8 Week Multi-site Study of MYDAYIS® for Bipolar Depression

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This protocol is a Phase 2 multi-site study which aims to evaluate the safety and effectiveness of MYDAYIS® as adjunctive therapy for adults with bipolar depression. Results from this study WILL NOT be used to contribute to an approval of MYDAYIS ® for this indication.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
Lindner Center of HOPE
Treatments:
Amphetamine
Dextroamphetamine